| irinotecan / Generic mfg. |
NCT02283359: Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus |
|
|
| Terminated | 1a/1b | 3 | US | Selinexor, KPT-330, Irinotecan, Camptosar | H. Lee Moffitt Cancer Center and Research Institute | Esophageal Cancer, Gastric Cancer | 12/15 | 01/16 | | |
NCT00545545: Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma |
|
|
| Completed | 1b | 48 | RoW | Safety and efficacy of escalating doses, Safety and efficacy of escalating doses. | HiberCell, Inc. | Recurrent Colorectal Carcinoma, Progressive Colorectal Carcinoma | 12/09 | 12/09 | | |
NCT01189942: A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer |
|
|
| Completed | 1b | 18 | RoW | OMP-21M18 | OncoMed Pharmaceuticals, Inc., Novotech (Australia) Pty Limited | Colorectal Cancer | 02/11 | 02/11 | | |
NCT00719199: Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer |
|
|
| Terminated | 1b | 21 | US | IMO-2055, Cetuximab, FOLFIRI | EMD Serono | Colorectal Cancer | 04/11 | 08/11 | | |
NCT01286818: A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B) |
|
|
| Completed | 1b | 6 | Japan | Ramucirumab (IMC-1121B), IMC-1121B, Ramucirumab, LY3009806, Irinotecan, levofolinate, 5-Fluorouracil (5-FU) | Eli Lilly and Company | Colorectal Carcinoma | 02/12 | 03/12 | | |
|
NCT02620423: Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma |
|
|
| Completed | 1b | 11 | US | REOLYSIN®, Pelareorep, Chemotherapy, Gemcitabine, Irinotecan, Leucovorin, 5-fluorouracil, Pembrolizumab, KEYTRUDA® | Oncolytics Biotech | Pancreatic Adenocarcinoma | 03/18 | 08/18 | | |
|
NCT02327169: A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies |
|
|
| Completed | 1b | 81 | Europe, US | MLN2480, TAK-580, MLN0128, Alisertib, Paclitaxel, Cetuximab, Irinotecan | Millennium Pharmaceuticals, Inc. | Advanced Nonhematologic Malignancies | 07/18 | 07/18 | | |
NCT03035253: A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer |
|
|
| Terminated | 1b | 16 | US | OMP-305B83, bispecific monoclonal antibody, FOLFIRI, FOLFOX | OncoMed Pharmaceuticals, Inc. | Metastatic Colorectal Cancer | 09/18 | 12/18 | | |
NCT01485744: LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer |
|
|
| Completed | 1b | 39 | US | LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan, FOLFIRINOX, 5-FU, CPT-11 | Massachusetts General Hospital, Dana-Farber Cancer Institute | Pancreatic Cancer | 11/19 | 11/19 | | |
NCT04689347: 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. |
|
|
| Recruiting | 1b | 18 | Europe | Bevacizumab, Irinotecan, Leucovorin, 5Fluorouracil, Temozolomide | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Metastatic Colorectal Cancer | 12/22 | 01/23 | | |
CAPAFOUR, NCT04990037: A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma |
|
|
| Completed | 1b | 25 | Europe | CAN04, Nadunolimab, FOLFIRINOX | Cantargia AB | Metastatic Pancreatic Ductal Adenocarcinoma | 05/23 | 06/23 | | |
COSMIC-021, NCT03170960: Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors |
|
|
| Active, not recruiting | 1b | 1732 | Europe, US, RoW | cabozantinib, Cabometyx, XL184, atezolizumab, Tecentriq | Exelixis | Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer | 07/23 | 08/24 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT05557851: Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas |
|
|
| Recruiting | 1b | 36 | RoW | Minnelide | Minneamrita Therapeutics LLC | Metastatic Adenocarcinoma of the Pancreas | 06/24 | 12/24 | | |
ACTRN12614000552684: A Phase 1 study of Temozolomide, Irinotecan, and O6BG (O6-Benzylguanine) for Children with Recurrent or Resistant Neuroblastoma |
|
|
| Not yet recruiting | 1 | 24 | | | The Sydney Children's Hospitals Network, The Kids Cancer Project will provide funding for the manufacture of the O6BG drug. | Recurrent Neuroblastoma, Resistant neuroblastoma | | | | |
ACTRN12624000455561: Safety and efficacy of faecal transplant and chemotherapy in the management of pancreatic cancer |
|
|
| Not yet recruiting | 1 | 60 | | | Central Adelaide Local Health Network (CALHN), Department of Health and Aged Care - Medical Research Future Fund (MRFF) | non-resectable pancreatic cancer | | | | |
ACTRN12609000790246: Phase I trial of carboplatin in combination with irinotecan and paclitaxel split-dosed on days 1 and 8 |
|
|
| Completed | 1 | 20 | | | Hellenic Cooperative Oncology Group, Hellenic Cooperative Oncology Group | Patients with advanced refractory cancers | | | | |
| Withdrawn | 1 | 42 | | | Sun BioPharma Australia Pty Ltd , Sun BioPharma Australia Pty Ltd | Pancreatic Cancer | | | | |
NCT00001495: A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors |
|
|
| Completed | 1 | 40 | US | irinotecan (CPT-11) | National Cancer Institute (NCI) | Neoplasms | | 10/00 | | |
NCT00003109: Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors |
|
|
| Completed | 1 | 39 | US | irinotecan hydrochloride, raltitrexed | Fox Chase Cancer Center, National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 10/00 | 01/01 | | |
NCT00002988: Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma |
|
|
| Completed | 1 | 36 | US | carmustine, irinotecan hydrochloride | Duke University, National Cancer Institute (NCI) | Brain and Central Nervous System Tumors | 11/00 | 11/00 | | |
NCT00002939: Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer |
|
|
| Completed | 1 | 21 | US | irinotecan hydrochloride, paclitaxel | University of Chicago, National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 02/01 | 04/02 | | |
NCT00003710: Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 12 | US | irinotecan hydrochloride, mitomycin C | The University of Texas Health Science Center at San Antonio, National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 05/01 | 05/01 | | |
NCT00004051: Irinotecan in Treating Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 40 | US | irinotecan hydrochloride | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 07/01 | 12/09 | | |
NCT00003742: Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors |
|
|
| Completed | 1 | | US | cisplatin, irinotecan hydrochloride, paclitaxel | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 08/01 | 08/01 | | |
NCT00002759: Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma |
|
|
| Completed | 1 | 3 | US | cyclosporine, irinotecan hydrochloride, phenobarbital | National Cancer Institute (NCI) | Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Neutropenia, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific | 04/02 | | | |
NCT00003427: Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer |
|
|
| Completed | 1 | 36 | US | irinotecan hydrochloride, oxaliplatin | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer, Pancreatic Cancer, Small Intestine Cancer | 04/02 | 04/02 | | |
NCT00003463: Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas |
|
|
| Completed | 1 | | US | carmustine, irinotecan hydrochloride, polifeprosan 20 with carmustine implant, surgical procedure | Duke University, National Cancer Institute (NCI) | Brain and Central Nervous System Tumors | 07/02 | 07/02 | | |
NCT00005791: Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors |
|
|
| Completed | 1 | | US | cisplatin, fluorouracil, irinotecan hydrochloride | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 07/02 | 12/09 | | |
NCT00024141: Irinotecan Followed by Fluorouracil in Treating Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | | US | fluorouracil, irinotecan hydrochloride | Roswell Park Cancer Institute | Unspecified Adult Solid Tumor, Protocol Specific | 09/02 | 01/03 | | |
NCT00251407: Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies |
|
|
| Completed | 1 | 46 | US | Taxotere, Cisplatin, CPT-11 | Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital | Solid Tumor | 01/03 | 04/09 | | |
NCT00053144: Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia |
|
|
| Completed | 1 | | US | cytarabine, irinotecan hydrochloride | Roswell Park Cancer Institute, National Cancer Institute (NCI) | Leukemia | 02/03 | 03/03 | | |
NCT00004919: Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy |
|
|
| Completed | 1 | 30 | US | cisplatin, CACP, CDDP, CPDD, DDP, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, amifostine trihydrate, ethiofos, Ethyol, gammaphos, WR-2721, pharmacological study, pharmacological studies | National Cancer Institute (NCI) | Unspecified Childhood Solid Tumor, Protocol Specific | 03/03 | | | |
NCT00054288: Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors |
|
|
| Completed | 1 | | US | gemcitabine hydrochloride, irinotecan hydrochloride | Roswell Park Cancer Institute | Unspecified Adult Solid Tumor, Protocol Specific | 05/03 | 06/09 | | |
NCT00005068: Combination Chemotherapy In Treating Patients With Metastatic or Unresectable Solid Tumors |
|
|
| Completed | 1 | | US | fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin | Mayo Clinic, National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 06/03 | 06/03 | | |
NCT00003970: Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma |
|
|
| Completed | 1 | 60 | US | irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E | National Cancer Institute (NCI) | AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific | 10/03 | | | |
NCT00003484: Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors |
|
|
| Completed | 1 | 21 | US | carmustine, irinotecan hydrochloride, surgical procedure, iodine I 131 monoclonal antibody 81C6 | Darell D. Bigner, MD, PhD, National Cancer Institute (NCI) | Brain and Central Nervous System Tumors, Neuroblastoma | 11/03 | 03/10 | | |
NCT00006465: Combination Chemotherapy in Treating Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 22 | US | capecitabine, irinotecan hydrochloride, camptothecin-11, irinotecan, irinotecan HCl, oxaliplatin, diaminocyclohexane oxalatoplatinum, oxalatoplatin, oxalatoplatinum | Case Comprehensive Cancer Center, National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 11/03 | 04/05 | | |
NCT00006485: Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | | US | alvocidib, irinotecan hydrochloride | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 12/03 | | | |
NCT00024284: Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors |
|
|
| Completed | 1 | | US, Canada | carboplatin, irinotecan hydrochloride | Bristol-Myers Squibb, National Cancer Institute (NCI) | Unspecified Childhood Solid Tumor, Protocol Specific | 12/03 | 12/03 | | |
NCT00006000: SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | | US | cisplatin, irinotecan hydrochloride, semaxanib | Ohio State University Comprehensive Cancer Center, National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | | 03/04 | | |
NCT00044785: Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors |
|
|
| Terminated | 1 | 24 | US | triacetyluridine, fluorouracil, leucovorin, camptosar | Wellstat Therapeutics | Solid Tumors | | 03/04 | | |
NCT00005638: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer |
|
|
| Completed | 1 | | US | cisplatin, irinotecan hydrochloride, radiation therapy | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Esophageal Cancer, Gastric Cancer | 04/04 | 04/04 | | |
NCT00003711: Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors |
|
|
| Completed | 1 | | US | irinotecan hydrochloride, pemetrexed disodium | San Antonio Cancer Institute | Unspecified Adult Solid Tumor, Protocol Specific | | 09/04 | | |
NCT00020748: Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer |
|
|
| Completed | 1 | | US | epirubicin hydrochloride, irinotecan hydrochloride | Georgetown University, National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 10/04 | 10/04 | | |
NCT00016861: Irinotecan in Treating Children With Refractory or Progressive Solid Tumors |
|
|
| Completed | 1 | | US | irinotecan hydrochloride | Texas Children's Cancer Center | Unspecified Childhood Solid Tumor, Protocol Specific | | 01/05 | | |
NCT00006095: Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy |
|
|
| Completed | 1 | 20 | US, RoW | irinotecan hydrochloride, CPT-11, NSC #616348, vincristine sulfate, VCR, Oncovin, NSC #067574 | Children's Oncology Group, National Cancer Institute (NCI) | Unspecified Childhood Solid Tumor, Protocol Specific | 01/05 | 09/05 | | |
NCT00006025: Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma |
|
|
| Completed | 1 | | US | irinotecan hydrochloride, temozolomide | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI) | Brain and Central Nervous System Tumors | 01/05 | 12/07 | | |
NCT00083148: Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer |
|
|
| Completed | 1 | 12 | US | capecitabine, irinotecan hydrochloride | Roswell Park Cancer Institute | Breast Cancer | 03/05 | 09/06 | | |
NCT00062842: Study of Irinotecan on a Weekly Schedule in Children |
|
|
| Completed | 1 | 23 | US | Irinotecan, Onivyde, | Baylor College of Medicine | Cancer | 05/05 | 09/06 | | |
NCT00047762: Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer |
|
|
| Completed | 1 | | US | Erlotinib (aka Tarceva or OSI-774), Bevacizumab (aka Avastin or Rhu MAb VEGF) | Genentech, Inc. | Colorectal Cancer | | | | |
NCT00008424: Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants |
|
|
| Completed | 1 | 7 | US, Canada, RoW | irinotecan hydrochloride | Children's Oncology Group, National Cancer Institute (NCI) | Unspecified Childhood Solid Tumor, Protocol Specific | 09/05 | 09/06 | | |
NCT00215501: Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies |
|
|
| Completed | 1 | 54 | US | Capecitabine, 5-Fluorouracil (5-FU), Irinotecan, Cisplatin | Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital | Solid Tumor | 09/05 | 09/08 | | |
NCT00084721: Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer |
|
|
| Completed | 1 | 2 | US | celecoxib, irinotecan hydrochloride | Roswell Park Cancer Institute, National Cancer Institute (NCI) | Colorectal Cancer, Diarrhea | 10/05 | | | |
NCT00251888: CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto |
|
|
| Completed | 1 | 15 | Europe | campto (irinotecan), cisplatin (cisplatyl) | ARCAGY/ GINECO GROUP | Cervix Cancer | | 11/05 | | |
NCT00047242: UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 30 | US | 7-hydroxystaurosporine, irinotecan hydrochloride | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 02/06 | | | |
NCT00005951: Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma |
|
|
| Completed | 1 | | US | irinotecan hydrochloride, temozolomide | Duke University, National Cancer Institute (NCI) | Brain and Central Nervous System Tumors | 04/06 | 04/06 | | |
NCT00021073: Combination Chemotherapy in Treating Patients With Advanced Cancer |
|
|
| Completed | 1 | 90 | US | alvocidib, FLAVO, flavopiridol, HMR 1275, L-868275, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E | National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 04/06 | | | |
NCT00062127: Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 35 | US | irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, thalidomide, Kevadon, Synovir, THAL, Thalomid, pharmacological study, pharmacological studies | National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 05/06 | | | |
NCT00507091: Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination |
|
|
| Completed | 1 | 24 | Europe | ZD6474 (vandetanib) 100mg, ZACTIMA™, Irinotecan, Camptosar®, 5-Fluorouracil, 5-FU, Leucovorin, ZD6474 (vandetanib) 300mg | Genzyme, a Sanofi Company | Metastatic, Colorectal, Adenocarcinoma | 05/06 | 06/08 | | |
NCT00251797: A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors |
|
|
| Completed | 1 | 10 | US | Irinotecan, Camptosar, Thalidomide, Thalomid | University of New Mexico | Brain and Nervous System, Cancer | 06/06 | 06/06 | | |
NCT00026195: Irinotecan in Treating Aging Patients With Solid Tumors |
|
|
| Completed | 1 | 140 | US | irinotecan hydrochloride | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 06/06 | 06/06 | | |
NCT00003368: Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis |
|
|
| Completed | 1 | | US | irinotecan hydrochloride | National Cancer Institute (NCI), Alliance for Clinical Trials in Oncology | Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific | | 07/06 | | |
NCT00022308: Chemotherapy and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer |
|
|
| Completed | 1 | | US | cisplatin, irinotecan hydrochloride, radiation therapy | Fox Chase Cancer Center, National Cancer Institute (NCI) | Lung Cancer | 09/06 | 09/06 | | |
NCT00026364: ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer |
|
|
| Completed | 1 | 22 | US | fluorouracil, gefitinib, irinotecan hydrochloride, leucovorin calcium | National Cancer Institute (NCI) | Colorectal Cancer | 12/06 | | | |
NCT00132054: Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer |
|
|
| Completed | 1 | 30 | Japan | amrubicin hydrochloride, irinotecan hydrochloride | Japan Multinational Trial Organization | Lung Cancer | 12/06 | 11/08 | | |
NCT00539877: Phase I Study of Interperitoneal Chenotherapy in Patients With Gastric Adenocarainoma With Peritoneal Seeding |
|
|
| Completed | 1 | 17 | RoW | irinotecan | Samsung Medical Center | Stomach Neoplasms | 12/06 | 08/07 | | |
NCT00300027: Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies |
|
|
| Terminated | 1 | 50 | US | BMS-582664 | Bristol-Myers Squibb | Gastrointestinal Neoplasms | 12/06 | | | |
NCT00177853: Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer |
|
|
| Terminated | 1 | 23 | US | celecoxib, Celebrex, irinotecan, Camptosar, concurrent radiotherapy | University of Pittsburgh, Pharmacia and Upjohn | Pancreatic Cancer | 12/06 | 07/10 | | |
NCT00612638: Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas |
|
|
| Completed | 1 | 96 | US | Temodar, O6-BG, and Irinotecan, Temodar-Temozolomide, O6-Benzylguanine-O6-BG, Irinotecan-Camptosar-CPT 11 | Duke University, Keryx / AOI Pharmaceuticals, Inc., Pharmacia | Glioblastoma, Gliosarcoma | 01/07 | 07/08 | | |
NCT00249977: Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan |
|
|
| Completed | 1 | 21 | US | Capecitabine in Combination with Cisplatin and Irinotecan | University of New Mexico | Solid Tumors, Cancer | 08/07 | 01/09 | | |
NCT00112892: Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 36 | US | selenium, irinotecan hydrochloride | Roswell Park Cancer Institute | Unspecified Adult Solid Tumor, Protocol Specific | 09/07 | 12/07 | | |
NCT00101270: Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas |
|
|
| Completed | 1 | 24 | US | irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP | National Cancer Institute (NCI) | Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway Glioma, Recurrent Colon Cancer, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Melanoma, Recurrent Nasopharyngeal Cancer, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific | 09/07 | | | |
NCT00183846: Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers |
|
|
| Completed | 1 | 22 | US | irinotecan, radiation therapy | University of Southern California | Pancreatic Cancer, Gastric Cancer, Duodenum Cancer, Bile Duct Cancer | 10/07 | 07/09 | | |
NCT00079352: Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors |
|
|
| Completed | 1 | 24 | US | alvocidib, FLAVO, flavopiridol, HMR 1275, L-868275, gemcitabine hydrochloride, dFdC, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E | National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 10/07 | | | |
NCT00502567: A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors |
|
|
| Completed | 1 | 104 | US | AZD2171, cediranib, RECENTIN™., FOLFOX, 5-Fluorouracil, Leucovorin and Oxaliplatin, Pemetrexed, Alimta®, Pemetrexed disodium, Irinotecan (administered with & without Cetuximab), Campto®, Camptosar®, irinotecan hydrochloride, Docetaxel, Taxotere® | AstraZeneca | Advanced Solid Tumor | 11/07 | 06/11 | | |
NCT00222443: Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy |
|
|
| Completed | 1 | 40 | US | Irinotecan | University of Oklahoma | Lymphomas, Tumors | 12/07 | 12/07 | | |
NCT00403052: A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer |
|
|
| Terminated | 1 | 14 | US | 1018 ISS immunostimulatory oligonucleotide | Dynavax Technologies Corporation | Colorectal Neoplasms | 12/07 | 12/07 | | |
NCT00110357: Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors |
|
|
| Completed | 1 | 48 | US | Cetuximab + Irinotecan | Eli Lilly and Company | Cancer, Refractory Solid Tumor | 03/08 | 03/08 | | |
NCT00084877: Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors |
|
|
| Completed | 1 | 36 | US | triapine, 3-AP, OCX-191, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, laboratory biomarker analysis, pharmacological study, pharmacological studies | National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 07/08 | | | |
NCT00045604: Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer |
|
|
| Completed | 1 | | US | cisplatin, imatinib mesylate, irinotecan hydrochloride | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Lung Cancer | | | | |
NCT00004095: Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors |
|
|
| Completed | 1 | 38 | US | gemcitabine hydrochloride, irinotecan hydrochloride | Northwestern University, National Cancer Institute (NCI) | Bladder Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer | 10/08 | 10/08 | | |
NCT00119236: 17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors |
|
|
| Completed | 1 | 48 | US | tanespimycin, 17-AAG, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E | National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 10/08 | | | |
NCT00042874: Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors |
|
|
| Completed | 1 | 77 | US | alvocidib, FLAVO, flavopiridol, HMR 1275, L-868275, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, leucovorin calcium, CF, CFR, LV, laboratory biomarker analysis | National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 01/09 | | | |
NCT00718757: Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies |
|
|
| Completed | 1 | 4 | US | Dexamethasone, Irinotecan, Vincristine | St. Jude Children's Research Hospital | Non-Hodgkins Lymphoma, Hodgkin's Disease, Acute Lymphoblastic Leukemia | 01/09 | 01/09 | | |
NCT00052494: Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer |
|
|
| Completed | 1 | 9 | Canada | cisplatin, imatinib mesylate, irinotecan hydrochloride | University Health Network, Toronto, National Cancer Institute (NCI) | Lung Cancer | 02/09 | | | |
NCT00059761: Chemotherapy Combined With Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer |
|
|
| Completed | 1 | 36 | US | cisplatin, irinotecan hydrochloride, radiation therapy | Radiation Therapy Oncology Group, National Cancer Institute (NCI) | Lung Cancer | 03/09 | 11/13 | | |
NCT00563316: Effect of Panitumumab on the Pharmacokinetics of Irinotecan |
|
|
| Completed | 1 | 28 | US, Canada | Panitumumab, Vectibix, Irinotecan, Camptosar | Amgen | Metastatic Colorectal Cancer | 03/09 | 06/10 | | |
NCT00183859: Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan |
|
|
| Completed | 1 | 42 | US | irinotecan | University of Southern California | Adenocarcinoma, Gastric Cancer | 04/09 | 04/09 | | |
NCT00037804: Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction |
|
|
| Completed | 1 | | US | Irinotecan | Pfizer | Unspecified Adult Solid Tumor, Chemotherapy, Liver Dysfunction, Neoplasms, Solid Tumor | | | | |
NCT00220649: Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas |
|
|
| Completed | 1 | 25 | US | gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin | St. Luke's-Roosevelt Hospital Center, Sanofi | Pancreatic Neoplasms | | | | |
NCT00478634: A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 1 | 19 | US | RAD001, Cetuximab, Irinotecan | Novartis Pharmaceuticals | Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal | 09/09 | 09/09 | | |
NCT00062322: Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer |
|
|
| Completed | 1 | | US | cisplatin, irinotecan hydrochloride, conventional surgery, neoadjuvant therapy, radiation therapy | Fox Chase Cancer Center, National Cancer Institute (NCI) | Lung Cancer | | 10/09 | | |
NCT00601692: Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal Cancer |
|
|
| Completed | 1 | 27 | US | cisplatin, docetaxel, irinotecan hydrochloride, radiation therapy | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Esophageal Cancer | 12/09 | 12/09 | | |
TIROX, NCT00506207: A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy |
|
|
| Unknown status | 1 | 23 | RoW | S-1, Irinotecan, Oxaliplatin | National Cancer Center, Korea | Colorectal Neoplasm, Gastric Neoplasm, Secondary | | 12/09 | | |
NCT00986843: Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (Oratecan-102) |
|
|
| Completed | 1 | 14 | RoW | HM30181AK tablet + Irinotecan tablets | Hanmi Pharmaceutical Company Limited | Advanced Solid Malignancies | 02/10 | 09/12 | | |
NCT00046917: Combination Chemotherapy in Treating Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 13 | US | alvocidib, FLAVO, flavopiridol, HMR 1275, L-868275, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, cisplatin, CACP, CDDP, CPDD, DDP | National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 03/10 | | | |
NCT00186979: Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors |
|
|
| Completed | 1 | 34 | US | Irinotecan, ZD1839, Vincristine, Cefixime, Cefpodoxime. | St. Jude Children's Research Hospital, AstraZeneca, National Institutes of Health (NIH) | Solid Tumors | 03/10 | 03/10 | | |
NCT00979563: Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies |
|
|
| Completed | 1 | 15 | RoW | HM30181AK tablet + Irinotecan tablets | Hanmi Pharmaceutical Company Limited | Advanced Solid Malignancies | 03/10 | 11/10 | | |
NCT00101894: Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer |
|
|
| Completed | 1 | 119 | US | FOLFOX-4, AMG 706, Panitumumab (Part 1a only), FOLFIRI | Amgen | Rectal Cancer, Colon Cancer | 04/10 | 12/11 | | |
|
NCT00479583: Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX |
|
|
| Completed | 1 | 25 | US, Europe | BMS-690514 / FOLFIRI, BMS-690514 / FOLFOX | Bristol-Myers Squibb | Cancer | 04/10 | 04/10 | | |
